Results 51 to 60 of about 3,981,458 (213)

Oxaliplatin-induced immune thrombocytopenia in a patient with pancreatic cancer

European Journal of Case Reports in Internal Medicine
Oxaliplatin-induced immune thrombocytopenia is a rare but potentially serious complication of chemotherapy. We present the case of a 55-year-old man with stage 4 pancreatic carcinoma who developed immune thrombocytopenia during the 18th cycle of folinic ...
Mustafa Şentürk, Özden Altundağ
doaj   +1 more source

Resource Use and Costs Related to Hematological Complications of Chemotherapy: Cost of Illness Study Based on Data from Balkan Country with Recent History of Socioeconomic Transition

Iranian Journal of Public Health, 2022
Background: The administration of chemotherapy positively correlates with diverse adverse drug reactions, including the significant impact of hematological hazards such as anemia, leukopenia-neutropenia, thrombocytopenia, and pancytopenia.
Marina J. Kostić, Slobodan M. Janković, Jana V. Desnica, Stefan D. Lukić, Sara S. Mijailović, Marija Anđelković, Marijana Stanojević Pirković, Olivera Z. Milovanović, Marko Spasić, Tanja Vojinović, Dejana Ružić Zečević   +10 more
doaj   +1 more source

Supplemental Material1 - Supplemental material for Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

, 2019
Supplemental material, Supplemental Material1 for Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma by Abolfazl Razzaghdoust, Bahram Mofid and Masoumeh Zangeneh in Journal of Oncology Pharmacy ...
Abolfazl Razzaghdoust (7009736), Masoumeh Zangeneh (7009742), Bahram Mofid (7009739)   +2 more
core   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Discriminative value of platelet size indices for the identification of the mechanism of chemotherapy-induced thrombocytopenia

, 2011
Context: A biomarker for discriminating mechanisms of chemotherapy-induced thrombocytopenia (CIT) (i.e. increased platelet destruction and decreased platelet production) would be valuable in managing treatment.
van Solinge, WW, Egberts, TCG (Toine), Huisman, Anne, van den Berg, MJ (Maarten), Bemt, Patricia, Den Breeijen, H   +5 more
core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Supplemental Material2 - Supplemental material for Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

, 2019
Supplemental material, Supplemental Material2 for Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma by Abolfazl Razzaghdoust, Bahram Mofid and Masoumeh Zangeneh in Journal of Oncology Pharmacy ...
Abolfazl Razzaghdoust (7009736), Masoumeh Zangeneh (7009742), Bahram Mofid (7009739)   +2 more
core   +1 more source

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton, Sian M. Morgan, Richard A. Adams, Samantha Cox, Angharad A. Rudkin, Megan Fealey, Craig Barrington, Michelle D. Wood, Dyfrig A. Hughes   +8 more
wiley   +1 more source

GEMCITABINE INDUCED DROP IN PLATELET COUNTS: A CASE REPORT [PDF]

, 2017
Chemotherapy with anticancer drugs is known to be beneficial, but like a double-edged sword it as its own demerits in form of adverse effects. Cancer chemotherapy induced thrombocytopenia is troublesome and platin based regimens namely Carboplatin and ...
Sereen Rose Thomson, Balaji Ommurugan, Navin Patil, Amita Priya   +3 more
core   +3 more sources